Αποτελέσματα Αναζήτησης
We aim to evaluate the non-inferiority of an anthracycline-free or short-term regimen to the standard anthracycline-based regimen for operable patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Methods. It is a prospective, open-label, phase 3, randomized non-inferiority trial from June 1, 2010 to June 1, 2017.
19 Ιουν 2024 · In a multi-institutional retrospective analysis using the American Society of Clinical Oncology CancerLinQ database, we compared survival outcomes among T1a-c N0 HER2+ patients diagnosed between...
15 Μαρ 2021 · This review found cancer patients pay substantial out-of-pocket costs per month, most of which is spent on cancer medications, followed by caregiver expenses, and transport and travel expenses. Expenditures were highest among pediatric patients and their caregivers.
6 Αυγ 2020 · We compared the methods and results of publicly available cost-effectiveness evaluations performed by ICER and NICE of similarly assessed cancer drugs. Assessments were compared based on incremental cost-effectiveness ratio, comparator treatment, price, recommendation, and the design of the economic evaluation.
31 Ιουλ 2017 · An analysis of the SEER-Medicare database shows that outcomes and healthcare costs for the two chemotherapy regimens are similar, with one difference.
In health care delivery systems in which third-party payers (private or government) cover the costs of cancer treatment and the insured public has a presumed and possibly legal right of access to all approved drugs, the soaring price of cancer drugs poses at least 3 major problems.
9 Μαρ 2021 · Cancer treatment is a significant driver of healthcare costs worldwide, however, the economic impact of treating patients with anti-neoplastic agents is poorly elucidated. We conducted a systematic review and meta-analysis to estimate the direct costs associated with administering intravenous chemotherapy in an outpatient setting.
